## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT

In re application of:
 Robert T. Lyons

Serial No. Not yet assigned

Dated: Herewith

For:USE OF ANTIMICROBIAL PEPTIDES
 AS PRESERVATIVES IN OPHTHALMIC PREPARATIONS, INCLUDING SOLUTIONS, EMULSIONS, AND SUSPENSIONS

## ENTRY OF SEQUENCE LISTING

Commissioner for Patents Washington, DC 20231

Dear Sir:

Attached is the "Sequence Listing" which complies with the requirements of 37 CFR 1.821-1.825, for the above-identified application, in computer readable form (CRF) and paper form. The contents of the paper and computer readable copies are the same and include no new matter.

Respectfully submitted,

Frank J. Uxa

Attorney for Applicant

Reg. No. 25,612

4 Venture, Suite 300

Irvine, CA 92618

(949) 450-1750

Facsimile (494) 450-1764

## SEQUENCE LISTING

```
<110> Lynos, Robert T
<120> Use of ANtimicrobal Peptides as Preservatives in
      Ophthalmic Preparations, Including Solutions,
      Emulsions, and Suspentions
<130> 2973 ver 2
<140> not known
<141> 2001-05-30
<150> WO 96/25183
<151> 1996-08-22
<160> 14
<170> PatentIn Ver. 2.1
<210> 1
<211> 23
<212> PRT
<213> Xenopus laevis
<300>
<301> Lee et al.,
<302> High-Level Expression of Antimicrobal Peptide Mediated
      by a Fusion Partner Reinforcing Formation of Inclusion
      Bodies
<303> Biochem. Biophys. Res. Commun.
<304> 277
<306> 575-580
<307> Sept 21, 2000
<400> 1
Gly Ile Gly Lys Phe Leu His Ser Ala Gly Lys Phe Gly Lys Ala Phe
  1
                  5
                                      10
                                                           15
Val Gly Glu Ile Met Lys Ser
             20
<210> 2
<211> 23
<212> PRT
<213> Xenopus laevis
<400> 2
```

<210> 5 <211> 37

```
Gly Ile Gly Lys Phe Leu His Ser Ala Lys Lys Phe Gly Lys Ala Phe
  1
                   5
                                      10
                                                           15
Val Gly Glu Ile Met Asn Ser
             20
<210> 3
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<221> PEPTIDE
<222> (22)
<223> Xaa at position 22 is Lys-amide
<223> Description of Artificial Sequence: maginin analog
<400> 3
Gly Ile Gly Lys Phe Leu Lys Lys Ala Lys Lys Phe Gly Lys Ala Phe
  1
                   5
                                      10
                                                           15
Val Lys Ile Leu Lys Xaa
             20
<210> 4
<211> 22
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: maginin analog
<400> 4
Gly Ile Gly Lys Phe Leu Lys Lys Ala Lys Lys Phe Gly Lys Ala Phe
  1
                   5
                                      10
                                                           15
Val Lys Ile Leu Lys Lys
             20
```

```
<212> PRT
<213> silk moth
<400> 5
Lys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg
                   5
                                       10
                                                            15
Asp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala
              20
                                  25
                                                        30
Thr Gln Ile Ala Lys
         35
<210> 6
<211> 36
<212> PRT
<213> silk moth
<400> 6
Lys Trp Lys Val Phe Lys Lys Ile Glu Lys Met Gly Arg Asn Ile Arg
  1
                   5
                                      10
                                                           15
Asn Gly Ile Val Lys Ala Gly Pro Ala Ile Ala Val Leu Gly Glu Ala
             20
                                  25
                                                       30
Lys Ala Leu Gly
         35
<210> 7
<211> 38
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: analog of
      cecropin B
<400> 7
Met Pro Arg Trp Arg Leu Phe Arg Arg Ile Asp Arg Val Gly Lys Gln
  1
                  5
                                      10
                                                           15
Ile Lys Gln Gly Ile Leu Arg Ala Gly Pro Ala Ile Ala Leu Val Gly
```

obre

20 25 30 Asp Ala Arg Ala Val Gly 35 <210> 8 <211> 30 <212> PRT <213> human <400> 8 Ala Cys Tyr Cys Arg Ile Pro Ala Cys Ile Ala Gly Glu Arg Arg Tyr 1 5 10 15 Gly Thr Cys Ile Tyr Gln Gly Arg Leu Trp Ala Phe Cys Cys 20 25 30 <210> 9 <211> 29 <212> PRT <213> human <400> 9 Cys Tyr Cys Arg Ile Pro Ala Cys Ile Ala Gly Glu Arg Arg Tyr Gly 5 1 10 15 Thr Cys Ile Tyr Gln Gly Arg Leu Trp Ala Phe Cys Cys 20 25 <210> 10 <211> 30 <212> PRT <213> human <400> 10 Asp Cys Tyr Cys Arg Ile Pro Ala Cys Ile Ala Gly Glu Arg Arg Tyr 1 5 10 15 Gly Thr Cys Ile Tyr Gln Gly Arg Leu Trp Ala Phe Cys Cys

25

30

20

```
<210> 11
<211> 33
<212> PRT
<213> rabbit
<400> 11
Val Val Cys Ala Cys Arg Arg Ala Leu Cys Leu Pro Arg Glu Arg Arg
  1
                   5
                                       10
                                                           15
Ala Gly Phe Cys Arg Ile Arg Gly Arg Ile His Pro Leu Cys Cys Arg
             20
                                  25
                                                       30
Arg
<210> 12
<211> 11
<212> PRT
<213> cow
<400> 12
Arg Leu Cys Arg Val Val Ile Arg Val Cys Arg
                                       10
<210> 13
<211> 26
<212> PRT
<213> Artificial Sequence
<220>
<221> PEPTIDE
<222> (26)
<223> Xaa at position 26 is Ser-amide
<220>
<223> Description of Artificial Sequence: Hybrid
      antimicrobial peptide
Lys Trp Lys Leu Phe Lys Lys Ile Gly Ile Gly Ala Val Leu Lys Val
  1
                   5
                                      10
                                                           15
Leu Thr Thr Gly Leu Pro Ala Leu Ile Xaa
```

20

<210> 14 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (16) <223> Xaa at position 16 is Leu-amide <220> <223> Description of Artificial Sequence: Hybrid antimicrobial peptide <400> 14 Lys Trp Lys Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Xaa 1 5 10 15